Returns
| Series | 1 week | 1 month | 3 months | 6 months | YTD | 1 year | 3 years (ann.) | 5 years (ann.) | 10 years (ann.) | Since inception (ann.) |
|---|---|---|---|---|---|---|---|---|---|---|
| Market-price return | +2.90% | -0.40% | +4.23% | +10.64% | +7.73% | +17.44% | +4.83% | -1.04% | +2.86% | +2.56% |
| Market-price total return | +2.90% | +0.19% | +6.13% | +14.90% | +14.04% | +26.81% | +12.62% | +5.84% | +9.84% | +11.05% |
| NAV return | -0.57% | -0.86% | +2.97% | +7.62% | +2.50% | +9.58% | +3.36% | -0.36% | +3.26% | +2.88% |
| NAV total return | -0.57% | -0.28% | +4.79% | +11.63% | +8.28% | +17.89% | +10.55% | +6.25% | +10.23% | +11.24% |
Performance through Oct 14, 2026. Price and NAV returns are simple changes; total returns reinvest each distribution at the series value on its ex-date (first observation on/after). Periods of one year or less are cumulative; longer periods are annualised. Series are built from unadjusted prices plus the distribution record so no distribution is counted twice. Corporate actions: the vendor price series is split-adjusted; rights offerings and mergers are not restated — check Corporate Actions.
Growth of $10,000, five years
Risk statistics
| Statistic | Market price | NAV | Specification |
|---|---|---|---|
| Volatility, 1 year | 0.14% | 0.17% | annualised SD of daily total returns, √252 |
| Volatility, 3 years | 0.14% | 0.14% | as above |
| Volatility, 5 years | 0.15% | 0.14% | as above |
| Maximum drawdown, 3 years | -14.36% | -14.42% | peak-to-trough on the total-return index |
| Sharpe ratio, 3 years | 0.59 | 0.49 | excess over FRED DGS3MO (window average) (avg 4.52%), annualised |
| Sortino ratio, 3 years | 0.82 | 0.71 | downside deviation of excess returns |
| Beta vs. benchmark proxy, 3 years | 0.44 | — | SPY (U.S. equity ETF proxy), daily, aligned dates |
| Correlation, 3 years | 0.49 | — | as above |
| Observations (3y) | 751 | — | minimum 60; rankings require 500 |
Market-price and NAV volatility are different quantities and are never mixed. NAV volatility for funds holding stale-marked or illiquid assets can understate economic risk.
CEF Explorer research page for BlackRock Health Sciences Trust. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.